当前位置:首页 - 行情中心 - 益佰制药(600594) - 财务分析 - 现金流量表

益佰制药

(600594)

  

流通市值:28.55亿  总市值:28.55亿
流通股本:7.84亿   总股本:7.84亿

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金816,590,372.23425,937,159.042,150,921,833.981,691,422,707.13
  收到的税费返还7,046.24-3,189,148.111,051,843.96
  收到其他与经营活动有关的现金29,576,385.1921,132,630.9290,845,196.7733,881,091.33
  经营活动现金流入小计846,173,803.66447,069,789.962,244,956,178.861,726,355,642.42
  购买商品、接受劳务支付的现金201,328,786.75104,072,314.19445,324,871.82344,011,463.21
  支付给职工以及为职工支付的现金226,971,437.14130,301,113.35495,699,262.98381,217,750.61
  支付的各项税费65,164,812.6130,307,502.18165,541,054.17127,384,781.8
  支付其他与经营活动有关的现金288,567,252.81137,210,796.87881,685,777.55669,943,421.46
  经营活动现金流出小计782,032,289.31401,891,726.591,988,250,966.521,522,557,417.08
  经营活动产生的现金流量净额64,141,514.3545,178,063.37256,705,212.34203,798,225.34
二、投资活动产生的现金流量:
  取得投资收益收到的现金113,934.59113,934.5984,687.6636,878.89
  处置固定资产、无形资产和其他长期资产收回的现金净额782,391704,0006,903,944.2310,760
  投资活动现金流入小计896,325.59817,934.596,988,631.8947,638.89
  购建固定资产、无形资产和其他长期资产支付的现金13,612,774.017,595,763.1334,992,693.7720,850,212.57
  投资支付的现金20,000,000---
  支付其他与投资活动有关的现金---2,164,525.67
  投资活动现金流出小计33,612,774.017,595,763.1334,992,693.7723,014,738.24
  投资活动产生的现金流量净额-32,716,448.42-6,777,828.54-28,004,061.88-22,967,099.35
三、筹资活动产生的现金流量:
  取得借款收到的现金380,000,000255,000,000515,999,999.5427,999,999.5
  筹资活动现金流入小计380,000,000255,000,000515,999,999.5427,999,999.5
  偿还债务支付的现金392,659,999.5242,649,999.5754,797,667.66505,688,833.83
  分配股利、利润或偿付利息支付的现金10,380,459.425,163,05828,686,363.3321,925,742.93
  支付其他与筹资活动有关的现金25,271,403.82,814,903.835,082,856.288,523,223.28
  筹资活动现金流出小计428,311,862.72250,627,961.3818,566,887.27536,137,800.04
  筹资活动产生的现金流量净额-48,311,862.724,372,038.7-302,566,887.77-108,137,800.54
四、汇率变动对现金及现金等价物的影响-13,286.08-7,856.67-8,941.59-5,033.51
五、现金及现金等价物净增加额-16,900,082.8742,764,416.86-73,874,678.972,688,291.94
  加:期初现金及现金等价物余额445,132,630.97445,132,630.97519,007,309.87519,007,309.87
  期末现金及现金等价物余额428,232,548.1487,897,047.83445,132,630.97591,695,601.81
补充资料:
  净利润-78,460,579.89--335,341,885.11-
  资产减值准备30,578,373.02-159,485,265.14-
  固定资产和投资性房地产折旧67,533,301.49-147,848,642.19-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧67,533,301.49-147,848,642.19-
  无形资产摊销7,673,827.63-16,079,766.47-
  长期待摊费用摊销9,113,002.75-21,890,040.99-
  处置固定资产、无形资产和其他长期资产的损失-1,827,269.37-27,210,380.43-
  固定资产报废损失411,274.52-3,956,582.09-
  财务费用11,382,355.03-33,524,360.04-
  投资损失80,051.75-214,599.61-
  递延所得税-2,746,224.54-9,726,350.78-
  其中:递延所得税资产减少-1,736,255.77-12,528,536.1-
    递延所得税负债增加-1,009,968.77--2,802,185.32-
  存货的减少-8,288,361.35-76,677,456.55-
  经营性应收项目的减少87,799,984.35-145,721,217.84-
  经营性应付项目的增加-61,826,671.72--60,456,463.39-
  现金的期末余额428,232,548.1-445,132,630.97-
  减:现金的期初余额445,132,630.97-519,007,309.87-
  现金及现金等价物的净增加额-16,900,082.87--73,874,678.9-
公告日期2026-08-212026-04-232026-04-232025-10-30
审计意见(境内)标准无保留意见
TOP↑